What is Erste Group Bank’s Estimate for NVO FY2026 Earnings?

Posted by Stanley Muller on Sep 16th, 2026

Novo Nordisk A/S (NYSE:NVO – Free Report) – Erste Group Bank cut their FY2026 earnings per share estimates for Novo Nordisk A/S in a report issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.43 per share for the year, down from their prior forecast of $3.46. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.45 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.32 EPS.

NVO has been the subject of a number of other research reports. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a research report on Wednesday, August 12th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Thursday, August 27th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $64.94.

Get Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Stock Down 2.4%

Shares of Novo Nordisk A/S stock opened at $42.43 on Monday. The firm has a market cap of $189.43 billion, a PE ratio of 10.37, a P/E/G ratio of 1.46 and a beta of 0.74. The business’s 50 day simple moving average is $47.23 and its 200 day simple moving average is $43.74. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several hedge funds and other institutional investors have recently made changes to their positions in NVO. Franklin Resources Inc. lifted its stake in Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after acquiring an additional 717,719 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $287,660,000. Royal Bank of Canada increased its stake in shares of Novo Nordisk A/S by 3.2% during the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares during the last quarter. Markel Group Inc. raised its holdings in shares of Novo Nordisk A/S by 21.2% in the 4th quarter. Markel Group Inc. now owns 2,869,774 shares of the company’s stock valued at $146,014,000 after purchasing an additional 501,125 shares during the period. Finally, Natixis Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 4.1% in the 4th quarter. Natixis Advisors LLC now owns 2,661,238 shares of the company’s stock valued at $135,404,000 after purchasing an additional 105,703 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is currently 20.05%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Wegovy gained a new potential indication in China. Chinese regulators approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 drug approved there for the liver disease. The decision expands semaglutide’s addressable market beyond weight management and cardiovascular-risk reduction. Novo Nordisk Expands Wegovy’s Reach with China MASH Approval
Positive Sentiment: The company is expanding semaglutide’s reach among children. A landmark trial reportedly showed that children as young as six could benefit from semaglutide treatment, potentially creating a significant long-term market. However, adoption will depend on physician prescribing, parental acceptance and insurance or government reimbursement. Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption
Neutral Sentiment: Novo Nordisk has launched a global rebrand and cultural reset. The company will use “Novo” as its everyday operating name, introduce the “Lasting Health Starts Now” platform and implement “The Novo Way.” CEO Mike Doustdar is urging employees to become more customer-focused. Management views the changes as a way to improve speed, consumer appeal and competitiveness, but investors appear to want evidence of stronger products and execution rather than a branding initiative alone. Novo CEO urges staff to embrace more customer-focused culture
Negative Sentiment: Competition from Eli Lilly remains the primary concern. Reports characterize the rebrand as a response to Novo Nordisk losing momentum in obesity treatments, with Wall Street questioning the company’s next growth driver as Lilly gains ground. From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure
Negative Sentiment: Analyst concerns are adding to the selling pressure. Morgan Stanley downgraded NVO to Underweight, citing muted growth, patent exposure and intensifying competition. Other commentary highlights pricing pressure and reduced Medicaid coverage, which could weigh on future obesity-drug sales and profitability. Will Morgan Stanley’s NVO Downgrade Deepen Patent and Rival Woes?

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.